Gender May Influence the Immunosuppressive Actions of Prednisone in Young Patients With Inflammatory Bowel Disease.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 26 02 2021
accepted: 29 04 2021
entrez: 31 5 2021
pubmed: 1 6 2021
medline: 21 10 2021
Statut: epublish

Résumé

Although the use of glucocorticoids (GC) is well established, the therapeutic response to these agents often shows important interindividual differences, in particular among young patients with inflammatory bowel diseases (IBD). Currently, GC resistance or dependence cannot be predicted by clinical or laboratory findings. The aim of this study was to investigate the association of gender and age with GC efficacy and with the expression of Glucocorticoid-Induced Leucine Zipper (GILZ). One hundred thirty patients (mean age at enrolment 12.6 years, 53 Crohn's disease, 70 males) were enrolled in this retrospective study. IBD patients with active disease despite prednisone at a daily dose of up to 2 mg/kg over a period of 4 weeks were defined as steroid resistant. Patients who initially responded but relapsed upon dose reduction were considered steroid-dependent. Total RNA was extracted from biopsies of 14 patients (9 males) and the levels of GILZ mRNA were evaluated by real-time PCR. Association between clinical response to prednisone and the considered demographic variables was evaluated using logistic regression models. After 4 weeks of treatment, 112 patients were responders to prednisone and 18 were resistant; at this time-point, resistant patients were older than responders (p=0.032). After 12 weeks, 42, 71 and 12 patients were sensitive, dependent and resistant respectively; at this time-point, females were more prone than males to develop prednisone dependence vs a good response (p=0.028) while age had no effect. Age was associated with response both at 4 and 12 weeks in the subgroups of females: resistant patients were older than sensitive ones at 4 weeks (p=0.02). Likewise, at 12 weeks of therapy, dependent patients resulted older than sensitive ones (p=0.05). No association of age with prednisone response was found in males. In a subgroup of 14 patients (5 females), GILZ mRNA expression in intestinal biopsies was higher in males (p=0.0031). Patients with unfavorable response (7) presented lower GILZ expression at disease onset in comparison to the responder group (p=0.017). Older females with IBD have a higher incidence of prednisone unfavorable response and reduced intestinal expression of the GC pharmacodynamic marker GILZ.

Identifiants

pubmed: 34054855
doi: 10.3389/fimmu.2021.673068
pmc: PMC8158435
doi:

Substances chimiques

Immunosuppressive Agents 0
TSC22D3 protein, human 0
Transcription Factors 0
Prednisone VB0R961HZT

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

673068

Informations de copyright

Copyright © 2021 Lucafò, Bramuzzo, Selvestrel, Da Lozzo, Decorti and Stocco.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Endocrinology. 1980 Aug;107(2):566-72
pubmed: 7190095
Endocrinology. 2013 Jan;154(1):499-510
pubmed: 23183181
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):227-32
pubmed: 14694204
Dis Colon Rectum. 2006 Jan;49(1):74-9
pubmed: 16283565
Dig Liver Dis. 2008 Jan;40(1):12-5
pubmed: 17997370
Int J Mol Sci. 2019 Jan 21;20(2):
pubmed: 30669566
Front Immunol. 2019 Jul 17;10:1684
pubmed: 31379872
Therap Adv Gastroenterol. 2020 Apr 28;13:1756284820915043
pubmed: 32523620
JAMA Pediatr. 2015 Nov;169(11):1053-60
pubmed: 26414706
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3919-24
pubmed: 10760263
World J Gastroenterol. 2017 Sep 28;23(36):6628-6638
pubmed: 29085208
Inflamm Bowel Dis. 2018 Jan 18;24(2):387-393
pubmed: 29361085
Hepatology. 2007 Dec;46(6):1986-92
pubmed: 18046708
Mol Endocrinol. 1990 Dec;4(12):1866-73
pubmed: 1964489
Curr Med Chem. 2018;25(24):2855-2871
pubmed: 28933291
J Steroid Biochem. 1988 Jun;29(6):599-604
pubmed: 3386227
Front Immunol. 2018 Jul 23;9:1720
pubmed: 30083167
FASEB J. 2016 Feb;30(2):971-82
pubmed: 26581598
Science. 2009 Apr 17;324(5925):407-10
pubmed: 19372434
Clin Rheumatol. 2017 Aug;36(8):1765-1772
pubmed: 28601944
Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):87-93
pubmed: 28722800
Digestion. 2012;86 Suppl 1:11-5
pubmed: 23051721
World J Gastroenterol. 2011 Mar 7;17(9):1095-108
pubmed: 21448414
Science. 2017 May 26;356(6340):
pubmed: 28495876
Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1209-1223
pubmed: 30465611
Gastroenterology. 2009 Feb;136(2):530-41
pubmed: 18996377
Inflamm Bowel Dis. 2006 Dec;12(12):1093-100
pubmed: 17119382
Scand J Gastroenterol. 2012 Jul;47(7):745-50
pubmed: 22507033
J Clin Gastroenterol. 2011 Jan;45(1):e1-7
pubmed: 20697295
Sci Signal. 2010 Oct 12;3(143):ra74
pubmed: 20940427
Inflamm Bowel Dis. 2015 Nov;21(11):2619-24
pubmed: 26214808
J Clin Endocrinol Metab. 2000 Oct;85(10):3561-8
pubmed: 11061502
Front Immunol. 2020 Dec 16;11:606649
pubmed: 33424852
Rheumatol Int. 2015 Aug;35(8):1377-84
pubmed: 25663291
Int J Mol Sci. 2018 May 08;19(5):
pubmed: 29738455
Clin Pharmacol Ther. 2016 Sep;100(3):268-74
pubmed: 27007551
Neurol Neuroimmunol Neuroinflamm. 2018 Oct 15;5(6):e507
pubmed: 30345333
Annu Rev Immunol. 2010;28:573-621
pubmed: 20192811
Inflamm Bowel Dis. 2020 Jun 18;26(7):1017-1025
pubmed: 31961437
J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):37-48
pubmed: 12650700
Oncol Lett. 2019 Dec;18(6):5673-5680
pubmed: 31788039
Neuropsychopharmacology. 1997 Aug;17(2):100-9
pubmed: 9252985
Clin Pharmacokinet. 2005;44(1):61-98
pubmed: 15634032
Front Endocrinol (Lausanne). 2018 May 16;9:235
pubmed: 29867767

Auteurs

Marianna Lucafò (M)

Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.

Matteo Bramuzzo (M)

Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.

Davide Selvestrel (D)

Department of Life Sciences, University of Trieste, Trieste, Italy.

Prisca Da Lozzo (P)

Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.

Giuliana Decorti (G)

Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.

Gabriele Stocco (G)

Department of Life Sciences, University of Trieste, Trieste, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH